Madisch A, Melderis H, Mayr G, Sassin I, Hotz J
Klinik für Gastroenterologie, Allgemeines Krankenhaus Celle.
Z Gastroenterol. 2001 Jul;39(7):511-7. doi: 10.1055/s-2001-16142.
To assess the efficacy and safety of the commercially available herbal preparation (Iberogast, STW-5*) containing extracts from bitter candy tuft, chamomile flower, peppermint leaves, caraway fruit, licorice root, lemon balm leaves, angelica root, celandine herbs, milk thistle fruit and its research preparation STW-5-S (without bitter candy tuft) in patients with functional dyspepsia.
After a standardized diagnostic work-up and at least 7 days free of medication, 60 patients, diagnosed with functional dyspepsia, were recruited in a multicenter trial and randomly assigned to one of 3 treatment groups (STW-5, STW-5-S or placebo). Each patient received the treatment for 4 weeks. The main outcome variables were the improvement of a gastrointestinal symptom score (GIS), a sumscore consisted of 10 dyspeptic symptoms rated on a Likert scale. Dyspeptic symptoms were assessed at baseline, 2 and 4 weeks after treatment.
60 patients completed the trial (mean age 46.8 years, range 25-70, female 38 patients). Compared with placebo-group both herbal preparations STW-5 and STW-5-S showed a clinically significant improvement of GIS after 2 and 4 weeks of treatment (p < 0.001). No statistically significant difference could be observed between the efficacy of STW-5 and STW-5 S (p > 0.05), but a solid improvement of gastrointestinal symptoms could be achieved earlier with STW-5 than with its research preparation STW-5-S without bitter candy tuft (p = 0.023).
In patients with functional dyspepsia, the commercially available herbal preparation STW-5 and its modified dispense STW-5-S tested improved dyspeptic symptoms significantly better than placebo. The extract bitter candy tuft appeared to have an additive effect on dyspeptic symptoms.
评估市售草药制剂(伊贝戈斯特,STW - 5*)(含有屈曲花、洋甘菊花、薄荷叶、香菜果、甘草根、蜜蜂花叶、当归根、白屈菜、水飞蓟果实提取物)及其研究制剂STW - 5 - S(不含屈曲花)对功能性消化不良患者的疗效和安全性。
经过标准化诊断检查且至少停药7天后,60例被诊断为功能性消化不良的患者参加了一项多中心试验,并随机分配至3个治疗组之一(STW - 5、STW - 5 - S或安慰剂)。每位患者接受治疗4周。主要结局变量为胃肠道症状评分(GIS)的改善情况,该评分是一个由10种消化不良症状组成的总分,采用李克特量表进行评分。在基线、治疗后2周和4周对消化不良症状进行评估。
60例患者完成试验(平均年龄46.8岁,范围25 - 70岁,女性38例)。与安慰剂组相比,草药制剂STW - 5和STW - 5 - S在治疗2周和4周后GIS均有临床显著改善(p < 0.001)。STW - 5和STW - 5 - S的疗效之间未观察到统计学显著差异(p > 0.05),但与不含屈曲花的研究制剂STW - 5 - S相比,STW - 5能更早实现胃肠道症状的显著改善(p = 0.023)。
在功能性消化不良患者中,市售草药制剂STW - 5及其改良剂型STW - 5 - S在改善消化不良症状方面显著优于安慰剂。屈曲花提取物似乎对消化不良症状有附加作用。